CEREBROVASCULAR ACCIDENTS IN PATIENTS TREATED FOR CHOROIDAL NEOVASCULARIZATION WITH RANIBIZUMAB IN RANDOMIZED CONTROLLED TRIALS

201288 citationsJournal Article

Authors

Neil M. Bressler · Johns Hopkins University

David S. Boyer · Retina Vitreous Associates Medical Group

David F. Williams · ViteroRetinal Surgery

Abstract

This analysis provided some evidence, although not definitive, of a potential increased risk of CVA with ranibizumab versus control or with 0.5-mg versus 0.3-mg ranibizumab. Continued monitoring for CVA within clinical trials seems warrented.

Topics & Keywords

Retinal Diseases and Treatments Retinal and Optic Conditions Retinal Imaging and Analysis

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Retina

Volume 32, Issue 9, pp. 1821-1828

DOI: 10.1097/iae.0b013e31825db6ba

Field-Weighted Citation Impact: 11.66